pentobarbital will reduce the level or outcome of atogepant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Recommended atogepant dosage with concomitant use of solid or average CYP3A4 inducers is 30 mg or 60 mg qDay.These studies have sizeable limitations, and it is not very clear In case the observed ef